SOPH
SOPHiA GENETICS S.A.
SOPH lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
SOPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SOPH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
SOPH PE Valuation
SOPH has no meaningful PE right now: it lost money over the past year.
SOPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SOPH's losses to shrink, with revenue growing.
SOPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.15 | -$0.05 |
| Q1 2026 | -$1.18 | -$0.18 |
| Q4 2025 | -$1.17 | -$0.22 |
| Q3 2025 | -$1.12 | -$0.03 |
| Q2 2025 | -$1.10 | -$0.08 |
| Q1 2025 | -$1.00 | +$0.12 |
| Q4 2024 | -$0.95 | +$0.27 |
| Q3 2024 | -$1.09 | -$0.02 |
SOPH is still losing money, but less than at its worst: $1.15 per share over the past year, against $1.51 at its worst in late 2022.
SOPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23.3M | +27% |
| Q1 2026 | $21.7M | +22% |
| Q4 2025 | $21.7M | +22% |
| Q3 2025 | $19.5M | +23% |
| Q2 2025 | $18.3M | +16% |
| Q1 2025 | $17.8M | +13% |
| Q4 2024 | $17.7M | +4% |
| Q3 2024 | $15.9M | -2.8% |
SOPH's revenue has grown year over year for seven quarters in a row: $23M last quarter, up 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -86% | +15 points |
| Q1 2026 | -80% | +11 points |
| Q4 2025 | -83% | +15 points |
| Q3 2025 | -92% | +5.1 points |
| Q2 2025 | -101% | -6.4 points |
| Q1 2025 | -90% | +29 points |
| Q4 2024 | -98% | +13 points |
| Q3 2024 | -97% | +4.6 points |
SOPH's operating margin was −86% last quarter, up 15 points from the same quarter a year ago.
SOPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.4M | -$199K |
| Q1 2026 | -$17.1M | -$4.8M |
| Q4 2025 | -$9.3M | +$3.3M |
| Q3 2025 | -$8.9M | +$581K |
| Q2 2025 | -$10.2M | +$2.2M |
| Q1 2025 | -$12.2M | +$4.4M |
| Q4 2024 | -$12.5M | +$1M |
| Q3 2024 | -$9.5M | +$4.8M |
SOPH has burned cash in almost every quarter: −$46M over the past year, against −$44M the year before.
SOPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.7M shares |
| 1 year | +9.7% | +6.5M shares |
| 3 years | +14% | +9.3M shares |
| 5 years | +17% | +10.5M shares |
| Available history | +92% | +35.5M shares |
SOPH has 74M diluted shares, up 9.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SOPH hasn't bought back shares in the past year.
SOPH Net Leverage
SOPH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SOPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 56.5 | Neutral |
SOPH's weekly RSI is 59 (neutral) and its Stochastic is 57 (neutral).
SOPH PE vs Healthcare Sector
SOPH has no meaningful PE right now: it lost money over the past year.
SOPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.57 | 3.8% above |
| 20 week MA | $7.25 | 8.4% above |
| 50 week MA | $5.87 | 34% above |
| 100 week MA | $4.68 | 68% above |
| 200 week MA | $4.35 | 81% above |
SOPH is in an uptrend: it's above all five of its weekly moving averages, and 81% above its 200-week average.
SOPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.8 | $13.7 | -19% |
| 2022 | $13.7 | $2.85 | -79% |
| 2023 | $2.85 | $4.71 | +65% |
| 2024 | $4.71 | $3.36 | -29% |
| 2025 | $3.36 | $4.73 | +41% |
| 2026 YTD | $4.73 | $7.86 | +66% |
SOPH is up 66% so far in 2026, after finishing lower in three of the previous five years.